ORIC Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ORIC Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
ORIC Pharmaceuticals: 7 sponsored US clinical trials, 3 recruiting.
ORIC Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 2 trials.
Upper-quartile sponsor footprint
ORIC Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
NCT06816992
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
NCT05227144
Study of ORIC-101 in Combination With Enzalutamide
NCT04033328
Study of ORIC-101 in Combination With Anticancer Therapy
NCT03928314
Study of ORIC-101 in Healthy Adult Subjects
NCT03324555
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
Therapeutic Areas
What is open in the ORIC Pharmaceuticals pipeline
3 recruiting of 7 indexed (43% open); 2 completed (29%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ORIC Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
ORIC Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this ORIC Pharmaceuticals page
7 registered trials is a research-attention snapshot, not an endorsement of ORIC Pharmaceuticals or any single study.
- 3 of ORIC Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Solid Tumors is the condition ORIC Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ORIC Pharmaceuticals pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.